The observational study conducted by Janssen Korea, Ltd. aimed to correlate changes in attention measures with caregiver burden in Alzheimer's patients treated with Galantamine. Given the increasing prevalence of Alzheimer's disease and the growing market for dementia therapies, this study could provide valuable insights into the efficacy of Galantamine in improving both patient outcomes and caregiver experiences. The results may strengthen Janssen's position in the Alzheimer's treatment market, particularly against competitors focusing on similar cholinergic pathways. However, the observational nature of the study limits the ability to draw definitive conclusions about causality, which may affect the commercial viability of Galantamine as a first-line treatment option.